Hengrui Pharma (HKG: 01276) has announced that its major product, Iohexol Injection, has been newly included in the National Essential Medicines List (2026 Edition).
This inclusion follows a joint notification issued by the National Health Commission, the National Administration of Traditional Chinese Medicine, and the National Disease Control and Prevention Administration. The updated list is scheduled to take effect from September 1, 2026.